

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

WYETH,

Plaintiff,

V.

IMPAX LABORATORIES, INC.,

Defendant.

PUBLIC VERSION

C. A. No. 06-222 (JJF)

Confidential Version Filed: November 15, 2007

Public Version Filed: December 28, 2007

**DECLARATION OF KAREN JACOBS LOUDEN IN SUPPORT OF
WYETH'S OPENING BRIEF IN SUPPORT OF ITS
MOTION TO STRIKE PARAGRAPHS 72-73, 81-84, 129-30 AND
133-36 OF THE REBUTTAL EXPERT REPORT OF ARTHUR H. KIBBE, Ph.D.**

I, Karen Jacobs Loudon, hereby declare as follows:

1. I am a partner with the law firm of Morris, Nichols, Arsht & Tunnell LLP. I am one of the attorneys representing Wyeth in the current litigation.
2. Attached hereto as Exhibit A is a true and correct copy of the Rebuttal Expert Report of Arthur H. Kibbe, Ph.D. dated October 31, 2007.
3. Attached hereto as Exhibit B is a true and correct copy of excerpts from Defendant Impax Laboratories, Inc.'s Responses to Plaintiff's First Set of Interrogatories (Nos. 1-13), dated July 26, 2006.
4. Attached hereto as Exhibit C is a true and correct copy of excerpts from Defendant Impax Laboratories, Inc.'s First Amended Responses to Plaintiff's First Set of Interrogatories (Nos. 1-13), dated October 10, 2006.
5. Attached hereto as Exhibit D is a true and correct copy of excerpts from Defendant Impax Laboratories, Inc.'s Second Amended Responses to Plaintiff's First Set of Interrogatories (Nos. 1-13), dated January 12, 2007.

6. Attached hereto as Exhibit E is a true and correct copy of Wyeth's Proposed Construction of Claim Terms, dated April 13, 2007.


7. Attached hereto as Exhibit F is a true and correct copy of an April 13, 2007 letter from S. Ernst to L. Wadler setting forth Impax's proposed claim constructions.

8. Attached hereto as Exhibit G is a true and correct copy of April 23 and 24, 2007 letters between D. Durie and L. Wadler.

9. Attached hereto as Exhibit H is a true and correct copy of an April 26, 2007 letter from L. Wadler to P. Blizzard.

10. Attached hereto as Exhibit I is a true and correct copy of the Order Resolving Vestar's Motions for Reconsideration in *The Liposome Co., Inc. v. Vestar, Inc.*, Civil Action No. 92-332 (RRM) (D. Del. Nov. 24, 1993).

I declare under penalty of perjury that the foregoing is true and correct, and that this declaration was executed on this 15th day of November, 2007.


Karen Jacobs Louden (#2881)

1314127

CERTIFICATE OF SERVICE

I, the undersigned, hereby certify that on December 28, 2007, I electronically filed the foregoing with the Clerk of the Court using CM/ECF, which will send notification of such filing(s) to the following:

Mary B. Matterer
MORRIS JAMES LLP

I also certify that copies were caused to be served on December 28, 2007 upon the following in the manner indicated:

BY E-MAIL AND HAND

Mary B. Matterer
MORRIS JAMES LLP
500 Delaware Avenue, Suite 1500
Wilmington, DE 19899

BY E-MAIL

Joseph C. Gratz
Daralyn J. Durie
KEKER & VAN NEST LLP
710 Sansome Street
San Francisco, CA 94111-1704

/s/ Karen Jacobs Loudon (#2881)

Karen Jacobs Loudon (#2881)
klouden@mnat.com

EXHIBIT A

FULLY REDACTED

EXHIBIT B

FULLY REDACTED

EXHIBIT C

FULLY REDACTED

EXHIBIT D

FULLY REDACTED

EXHIBIT E

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

WYETH,

Plaintiff,

v.

IMPAX LABORATORIES, INC.,

Defendant.

)
)
)
)
) C. A. No. 06-222 (JJF)
)
)
)
)
)

WYETH'S PROPOSED CONSTRUCTION OF CLAIM TERMS

Wyeth, pursuant to ¶ 8 of the Court's July 13, 2006 Rule 16 Scheduling Order, submits the following construction of terms of the asserted claims of the patents in suit that have been identified by either party as requiring construction. Wyeth reserves the right to modify or supplement its construction because discovery is in progress. Wyeth further reserves the right to modify or supplement its construction to the extent Impax identifies additional claim terms that it considers in dispute.

CLAIM TERM	WYETH'S CONSTRUCTION
with diminished incidence(s) of nausea and emesis	The degree and/or frequency of nausea and emesis from the extended release formulation administered once-a-day is less than what would be experienced by patients receiving the same total daily dose of an immediate release formulation that is administered at least twice a day.
extended release formulation	A formulation, other than a hydrogel tablet, which releases the active ingredient at a slower rate than the immediate release formulation of the active ingredient such that the dosing frequency is once-a-day rather than the plural daily dosing for the immediate release formulation.
encapsulated	Filled into a pharmaceutically acceptable capsule.

CERTIFICATE OF SERVICE

I, Karen Jacobs Louden, hereby certify that copies of the foregoing were caused to be served this 13th day of April, 2007 upon the following in the manner indicated:

BY HAND

Mary B. Matterer
Morris James LLP
222 Delaware Avenue
P.O. Box 2306
Wilmington, DE 19899

BY EMAIL

M. Patricia Thayer
John M. Benassi
Jessica R. Wolf
Heller Ehrman LLP
4350 La Jolla Village Drive
San Diego, CA 92102

/s/ Karen Jacobs Louden

Karen Jacobs Louden (#2881)

EXHIBIT F

HellerEhrman_{LLP}

April 13, 2007

Via E-mail and U.S. Mail

Samuel F. Ernst
 Sam.Ernst@HellerEhrman.com
 Direct +1 (415) 772-6964
 Direct Fax +1 (415) 772-1759
 Main +1 (415) 772-6000
 Fax +1 (415) 772-6268

40443.0005

Linda A. Wadler, Esq.
 Finnegan, Henderson, Farabow,
 Garrett & Dunner, L.L.P.
 901 New York Ave., N.W.
 Washington, D.C. 20001-4413

Re: *Wyeth v. Impax Laboratories*, No. 06-222 (D. Del.)

Dear Linda:


Pursuant to paragraph 8 of the Court's July 13, 2006 Scheduling Order and the parties' agreements with respect to the same as set forth in Ms. Rudolph's letter of today, the following are Impax's proposed claim constructions:

Claim Term	Impax's Proposed Construction
with diminished incidence(s) of nausea and emesis	a decrease in the number of patients suffering from nausea and vomiting compared to patients receiving the same total daily dose of an immediate release formulation that is administered at least twice a day
extended release formulation	a formulation comprising venlafaxine, microcrystalline cellulose, and, optionally, HPMC coated with a mixture of ethyl cellulose and HPMC in an amount needed to provide a specific unit dosage administered once-a-day to provide a therapeutic blood plasma level of venlafaxine over the entire 24-hour period of administration
for eliminating the troughs and peaks of drug concentration in a patient's blood plasma attending the therapeutic metabolism of plural daily doses of venlafaxine hydrochloride	the peak(s) and trough(s) due to the "therapeutic metabolism" of any second or third dose given in a single day is eliminated by dosing only once every 24 hours
spheroid	one or more particles that are generally shaped like a sphere, although they do not have to be perfectly round

HellerEhrman LLP

Linda Wadler, Esq.
April 13, 2007
Page 2

Best regards,

A handwritten signature in black ink, appearing to be 'S. Ernst', with a long horizontal line extending to the right.

Samuel F. Ernst

cc: Jessica R. Wolff, Esq.
Daniel N. Kassabian, Esq.
Eric L. Lane, Esq.
Daralyn J. Durie, Esq.
Asim Bhansali, Esq.
Paula L. Blizzard, Esq.
Mary B. Matterer, Esq.
Basil J. Lewris, Esq.
James K. Hammond, Esq.
Barbara R. Rudolph, Esq.
Karen Jacobs Loudon, Esq.

EXHIBIT G

LAW OFFICES
KEKER & VAN NEST
LLP

710 SANSOME STREET
SAN FRANCISCO, CA 94111-1704
TELEPHONE (415) 391-5400
FAX (415) 397-7188
WWW.KVN.COM

DARALYN J. DURIE
DDURIE@KVN.COM

April 23, 2007

VIA EMAIL & U.S. MAIL

Linda A. Wadler, Esq.
Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001

Re: Wyeth v. Impax Laboratories, Inc.

Dear Ms. Wadler:

I write in response to your April 23, 2007 letter to Daniel Kassabian. First, Impax has no additional claim terms to be construed at this time. Second, Impax understands your letter to mean that Wyeth accepts Impax's construction of the term "spheroids," as set forth in Samuel Ernst's April 13, 2007 letter to you. Subject to this understanding, Impax is amenable to indicating to the court that the parties are in agreement on this term.

Very truly yours,

A handwritten signature in black ink, appearing to read "Daralyn J. Durie" followed by a stylized flourish or initials.

Daralyn J. Durie

DJD/jcg

cc: Barbara R. Rudolph, Ph.D., Esq. (via email only)
Robert A. Pollock, Ph.D., Esq. (via email only)
Mary B. Matterer, Esq. (via email only)
Daniel N. Kassabian, Esq. (via email only)



901 New York Avenue, NW ■ Washington, DC 20001-4413 ■ 202.408.4000 ■ Fax 202.408.4400
www.finnegan.com

LINDA A. WADLER
202.408.4037
linda.wadler@finnegan.com

April 24, 2007

Daralyn J. Durie, Esq.
Keker & Van Nest LLP
710 Sansome Street
San Francisco, CA 94111

Via E-mail
Confirmation by U.S. mail

Wyeth v. Impax Laboratories, Inc., Civil Action No.: 06-222 (D. Del.)

Dear Daralyn:

In response to your letter of April 23rd, Wyeth believes the parties are in agreement on the construction of the term "spheroid" - the identification of examples is not necessary. Since Impax has not offered an alternative construction to Wyeth's construction of the terms "encapsulated" and "a method for providing a therapeutic blood plasma concentration of venlafaxine over a twenty four hour period," we understand that we also can indicate to the Court that the parties are in agreement on those terms as well. If Impax disagrees, please let us know promptly.

Finally, we are not available at 2:00 pm EDT tomorrow for a meet and confer. Would you be available at 5:30 pm EDT/2:30 pm PDT? Please let us know later today.

Sincerely,

A handwritten signature in cursive script, appearing to read 'Linda'.

Linda A. Wadler

LAW/sas

cc: Mary B. Matterer, Esq. (via e-mail)
Jessica Wolff, Esq. (via e-mail)
Daniel Kassabian, Esq. (via e-mail)
M. Patricia Thayer, Esq. (via e-mail)
Samuel F. Ernst, Esq. (via e-mail)
Eric L. Lane, Esq. (via e-mail)
Karen Jacobs Loudon, Esq. (via e-mail)

EXHIBIT H



901 New York Avenue, NW • Washington, DC 20001-4413 • 202.408.4000 • Fax 202.408.4400
www.finnegan.com

LINDA A. WADLER
202.408.4037
linda.wadler@finnegan.com

April 26, 2007

Paula J. Blizzard, Esq.
Keker & Van Nest LLP
710 Sansome Street
San Francisco, CA 94111

Via E-mail
Confirmation by U.S. mail

Wyeth v. Impax Laboratories, Inc., Civil Action No.: 06-222 (D. Del.)

Dear Paula:

I am writing to summarize the parties' positions at the April 25th meet and confer telephone conference regarding claim construction. First, the parties agreed that the only claim terms remaining in dispute are:

- 1) "with diminished incidence(s) of nausea and emesis,"
- 2) "extended release formulation," and
- 3) "A method for eliminating the troughs and peaks of drug concentration in a patients blood plasma attending the therapeutic metabolism of plural daily doses of venlafaxine hydrochloride."

Although the parties discussed whether a potential compromise was possible on the claim terms listed above, no compromise was reached. Although Wyeth has considered your comments on the third term listed above, Wyeth intends to maintain the construction of that term as stated in its April 13, 2007 proposed construction of claim terms.

The parties are in agreement on the construction of the terms "spheroid," as reflected in my letter of April 23 to Mr. Kassabian and Impax's April 13, 2007 proposed construction of claim terms. In addition, Impax is agreement with the construction of the terms "encapsulated," and "a method for providing a therapeutic blood plasma concentration of venlafaxine over a twenty four hour period" as set forth in Wyeth's April 13, 2007 proposed construction of claim terms.

Although service of the opening Markman briefs via e-mail and hand and service of the exhibits (if too voluminous for e-mail) by next day delivery was discussed, we also

FINNEGAN
HENDERSON
FARABOW
CARRETT &
DUNNER LLP

Paula J. Blizzard, Esq.
April 26, 2007
Page 2

agreed that our respective local counsel would be in touch with each other to further discuss and confirm the mechanics of service of the opening Markman briefs.

Sincerely,



Linda A. Wadler

LAW/sas

cc: Mary B. Matterer, Esq. (via e-mail)
Jessica Wolff, Esq. (via e-mail)
Daniel Kassabian, Esq. (via e-mail)
M. Patricia Thayer, Esq. (via e-mail)
Samuel F. Ernst, Esq. (via e-mail)
Eric L. Lane, Esq. (via e-mail)
Karen Jacobs Loudon, Esq. (via e-mail)

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

Paula J. Blizzard, Esq.
April 26, 2007
Page 3

bcc: Lawrence Alaburda, Esq. (via e-mail)
Susan Lee, Esq. (via e-mail)
Jack B. Blumenfeld, Esq. (via e-mail)

EXHIBIT I

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

FILED

NOV 29 1993

THE LIPOSOME COMPANY, INC.,)

Plaintiff,)

v.)

VESTAR, INC.,)

Defendant.)

TIME _____
CLERK, U.S. DISTRICT COURT
DISTRICT OF DELAWARE

Civil Action No. 92-332-RRM

ORDER RESOLVING VESTAR'S MOTIONS FOR RECONSIDERATION

Vestar has moved for reconsideration of two decisions made by the Court during the November 12, 1993 Pretrial Conference. First, it has moved for reconsideration of the Court's decision to preclude it from calling Thomas D. Kiley as an expert witness. Second, it has moved for reconsideration of the Court's decision that plaintiff could assert the doctrine of equivalents as a basis for infringement. The Court having reviewed the additional papers submitted by the parties on these motions,

IT IS ORDERED AS FOLLOWS:

1. Vestar's Motion for Reconsideration as to Plaintiff's Motion In Limine to Preclude Defendant's Rebuttal Expert from Testifying (Docket Item 131) Vestar's Motion for reconsideration of the Court's decision to preclude it from calling Thomas D. Kiley to testify as an expert is denied. Vestar failed to identify Mr. Kiley as an expert within the time period provided by the Court in the Scheduling Order in this matter. The deadlines in that Order are consistent with the Court's interest in setting the time for completion of discovery

and ensuring compliance with appropriate requested discovery in a timely fashion. See 28 U.S.C. § 473(a)(2)(C).

2. Vestar's Motion to Exclude from this Case Plaintiff's Claim of Infringement Under the Doctrine of Equivalents (Docket Item 130) Vestar's Motion to preclude Liposome from relying on the doctrine of equivalents is granted. In its Motion, Vestar has shown that during the period for discovery it served an interrogatory on Liposome asking it to state whether it alleged claims were infringed under the doctrine of equivalents. In responding, Liposome did not report that it intended to allege infringement under the doctrine of equivalents. Liposome did not disclose it intended to rely on the doctrine of equivalents until November 7, 1993, after the date for completion of discovery. As Liposome failed to identify this contention in response to Vestar's discovery request, the Court will preclude it from relying on it at trial.


United States District Judge

Dated: November 24, 1993